Research programme: tubulin targeting agents - Veru Healthcare

Drug Profile

Research programme: tubulin targeting agents - Veru Healthcare

Alternative Names: APP 111

Latest Information Update: 19 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ohio State University
  • Developer Veru Healthcare
  • Class Small molecules
  • Mechanism of Action Androgen receptor antagonists; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 30 Sep 2015 Aspen Park Pharmaceuticals acquires the worldwide rights from the Ohio State University, to develop APP 111 and its analogues
  • 30 Sep 2015 Aspen Park Pharmaceuticals has over 21 issued, allowed, and pending patents for APP 111
  • 30 Sep 2015 Preclinical trials in Prostate cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top